We observed co-upregulation of WDR77 and PRMT5 in melanoma, suggesting that patients with high WDR77 expression may benefit from PRMT5-targeted therapies currently under clinical evaluation (59, 60). This evidence concerns the gene PRMT5 and melanoma.